Michelle Haber

16.5k total citations · 3 hit papers
229 papers, 9.8k citations indexed

About

Michelle Haber is a scholar working on Molecular Biology, Neurology and Oncology. According to data from OpenAlex, Michelle Haber has authored 229 papers receiving a total of 9.8k indexed citations (citations by other indexed papers that have themselves been cited), including 126 papers in Molecular Biology, 105 papers in Neurology and 58 papers in Oncology. Recurrent topics in Michelle Haber's work include Neuroblastoma Research and Treatments (103 papers), Acute Lymphoblastic Leukemia research (43 papers) and Cancer therapeutics and mechanisms (39 papers). Michelle Haber is often cited by papers focused on Neuroblastoma Research and Treatments (103 papers), Acute Lymphoblastic Leukemia research (43 papers) and Cancer therapeutics and mechanisms (39 papers). Michelle Haber collaborates with scholars based in Australia, United States and United Kingdom. Michelle Haber's co-authors include Murray D. Norris, Michelle J. Henderson, Jamie I. Fletcher, Glenn M. Marshall, Maria Kavallaris, Catherine A. Burkhart, Susan L. Cohn, Susan Band Horwitz, Janice Madafiglio and Belamy B. Cheung and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Michelle Haber

222 papers receiving 9.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ABC transporters in cancer: more than just drug efflux pumps

2010 833 citations Jamie I. Fletcher, Michelle Haber et al. profile →
Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.

1997 502 citations Maria Kavallaris, Catherine A. Burkhart et al. profile →
Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion

2020 280 citations Emanuele Valli, Federica Saletta et al. Cancer Research profile →

Peers

Countries citing papers authored by Michelle Haber

Since Specialization

Citations

This map shows the geographic impact of Michelle Haber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Haber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Haber more than expected).

Fields of papers citing papers by Michelle Haber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Haber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Haber. The network helps show where Michelle Haber may publish in the future.

Co-authorship network of co-authors of Michelle Haber

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Haber. A scholar is included among the top collaborators of Michelle Haber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Haber. Michelle Haber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy 2025 ·Cancer Research Communications ·(unknown), Jamie I. Fletcher, (unknown), Loretta M. S. Lau, M. Emmy M. Dolman, Jie Mao, (unknown), (unknown), (unknown), Alvin Kamili, Biljana Dumevska, (unknown), Jennifer A. Chan, Donna L. Senger, Stephanie A. Grover, David Malkin, Michelle Haber, Jason N. Berman	0
2	P-glycoprotein as a chemotherapy resistance mechanism and biomarker of poor response in high-risk neuroblastoma 2025 ·SHILAP Revista de lepidopterología ·Caroline Atkinson, Alvin Kamili, (unknown), (unknown), (unknown), Federica Saletta, (unknown), (unknown), (unknown), Rosa Mistica C. Ignacio, Maria Kavallaris, Andrew J. Gifford, Richard B. Lock, Murray D. Norris, Michelle Haber, Chelsea Mayoh, Christa E. Nath, Toby N. Trahair, Jamie I. Fletcher	0
3	Donor T cells for CAR T cell therapy 2022 ·Biomarker Research ·(unknown), Ning Xu, Robert Nordon, Michelle Haber, Kenneth Micklethwaite, Alla Dolnikov	24
4	Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas 2021 ·Nature Communications ·Aaminah Khan, Laura D. Gamble, Dannielle Upton, (unknown), Denise Yu, Anahid Ehteda, (unknown), Chelsea Mayoh, Steven Hébert, Nada Jabado, Claudia L. Kleinman, Mark R. Burns, Murray D. Norris, Michelle Haber, Maria Tsoli, David S. Ziegler	84
5	Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in CRLF2 -Rearranged Ph-like ALL 2020 ·Molecular Cancer Research ·(unknown), Ling Zhong, Chelsea Mayoh, Murray D. Norris, Michelle Haber, Glenn M. Marshall, Mark J. Raftery, Richard B. Lock	2
6	Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC–Driven Cancer Progression 2020 ·Cancer Research ·Jixuan Gao, MoonSun Jung, Chelsea Mayoh, (unknown), Katherine M. Hannan, Jamie I. Fletcher, Alvin Kamili, Andrew J. Gifford, Eric Kusnadi, Richard B. Pearson, Ross D. Hannan, Michelle Haber, Murray D. Norris, Klaartje Somers, Michelle J. Henderson	18
7	Recurrent SPECC1L–NTRK fusions in pediatric sarcoma and brain tumors 2020 ·Molecular Case Studies ·Dong-Anh Khuong-Quang, Lauren M. Brown, Marie Wong, Chelsea Mayoh, Alexandra Sexton‐Oates, Amit Kumar, Mark Pinese, (unknown), Loretta M. S. Lau, Louise Ludlow, Andrew J. Gifford, Michael Rodriguez, Jayesh Desai, Stephen B. Fox, Michelle Haber, David S. Ziegler, Jordan R. Hansford, Glenn M. Marshall, Mark J. Cowley, Paul G. Ekert	5
8	Optimization of a clofarabine‐based drug combination regimen for the preclinical evaluation of pediatric acute lymphoblastic leukemia 2019 ·Pediatric Blood & Cancer ·(unknown), (unknown), (unknown), Jurgen Langenhorst, Alan V. Boddy, (unknown), Rosemary Sutton, Nicola C. Venn, Arjen M. Punt, Vanessa Tyrrell, Michelle Haber, Toby N. Trahair, Loretta M. S. Lau, Glenn M. Marshall, Richard B. Lock	4
9	Network Modeling of microRNA–mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN 2018 ·Cancer Research ·(unknown), Daniel R. Carter, Bing Liu, Chelsea Mayoh, Anneleen Beckers, (unknown), Zsuzsanna Nagy, Sara De Brouwer, Bieke Decaesteker, Tzong‐Tyng Hung, Murray D. Norris, Michelle Haber, Tao Liu, Katleen De Preter, Frank Speleman, Belamy B. Cheung, Glenn M. Marshall	45
10	MYC -Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin 2016 ·Cancer Research ·(unknown), Sieu L. Tran, Michelle F. Maritz, Bing Liu, Cheng Kong, Stefania Purgato, Chen Yang, Jayne Murray, Amanda J. Russell, Claudia L. Flemming, Georg von Jonquières, Hilda A. Pickett, Wendy B. London, Michelle Haber, Preethi H. Gunaratne, Murray D. Norris, Giovanni Perini, Jamie I. Fletcher, Karen L. MacKenzie	36
11	A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers 2016 ·Cancer Research ·MoonSun Jung, Amanda J. Russell, Bing Liu, Joshy George, (unknown), Tao Liu, Anna DeFazio, David D.L. Bowtell, André Oberthuer, Wendy B. London, Jamie I. Fletcher, Michelle Haber, Murray D. Norris, Michelle J. Henderson	75
12	Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression 2016 ·Clinical Cancer Research ·Nicholas F. Evageliou, Michelle Haber, Annette Vu, Theodore W. Laetsch, Jayne Murray, Laura D. Gamble, Ngan Ching Cheng, Kangning Liu, (unknown), (unknown), David S. Ziegler, Hannah Webber, (unknown), Bruce Pawel, Glenn M. Marshall, Huaqing Zhao, Susan K. Gilmour, Murray D. Norris, Michael D. Hogarty	64
13	Folate Pathway Gene Polymorphisms and Risk of Childhood Brain Tumors: Results from an Australian Case–Control Study 2015 ·Cancer Epidemiology Biomarkers & Prevention ·Kathryn R. Greenop, Rodney J. Scott, John Attia, Carol Bower, Nicholas de Klerk, Murray D. Norris, Michelle Haber, Sarra E. Jamieson, Frank M. van Bockxmeer, Nicholas G. Gottardo, Lesley J. Ashton, Bruce K. Armstrong, Elizabeth Milne	6
14	Folate Pathway Gene Polymorphisms, Maternal Folic Acid Use, and Risk of Childhood Acute Lymphoblastic Leukemia 2014 ·Cancer Epidemiology Biomarkers & Prevention ·Elizabeth Milne, Kathryn R. Greenop, Rodney J. Scott, Michelle Haber, Murray D. Norris, John Attia, Sarra E. Jamieson, Margaret Miller, Carol Bower, Helen D. Bailey, (unknown), Geoffrey McCowage, Nicholas de Klerk, Frank M. van Bockxmeer, Bruce K. Armstrong	15
15	Targeting the Inhibitor of Apoptosis Proteins as a Novel Therapeutic Strategy in Medulloblastoma 2012 ·Molecular Cancer Therapeutics ·Joanna Keating, Maria Tsoli, Andrew R. Hallahan, Wendy J. Ingram, Michelle Haber, David S. Ziegler	13
16	Prognostic Significance of Promoter DNA Methylation in Patients with Childhood Neuroblastoma 2012 ·Clinical Cancer Research ·(unknown), Luke B. Hesson, Murray D. Norris, Glenn M. Marshall, Michelle Haber, Lesley J. Ashton	22
17	c-MYC Oncoprotein Dictates Transcriptional Profiles of ATP-Binding Cassette Transporter Genes in Chronic Myelogenous Leukemia CD34+ Hematopoietic Progenitor Cells 2011 ·Molecular Cancer Research ·Antônio Porro, Nunzio Iraci, Simona Soverini, Daniel Diolaiti, Samuele Gherardi, Carolina Terragna, Sandra Durante, Emanuele Valli, Thea Kalebic, Roberto Bernardoni, (unknown), Michelle Haber, Murray D. Norris, Michele Baccarani, Giovanni Martinelli, Giovanni Perini	38
18	N-Myc Regulates Expression of the Detoxifying Enzyme Glutathione Transferase GSTP1 , a Marker of Poor Outcome in Neuroblastoma 2011 ·Cancer Research ·Jamie I. Fletcher, Samuele Gherardi, Jayne Murray, Catherine A. Burkhart, Amanda J. Russell, Emanuele Valli, Janice Smith, André Oberthuer, Lesley J. Ashton, Wendy B. London, Glenn M. Marshall, Murray D. Norris, Giovanni Perini, Michelle Haber	12
19	Small-Molecule Multidrug Resistance–Associated Protein 1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Models of Neuroblastoma 2009 ·Cancer Research ·Catherine A. Burkhart, Fujiko Watt, Jayne Murray, Marina Pajic, Anatoly Prokvolit, Chengyuan Xue, Claudia L. Flemming, Janice Smith, Andrei A. Purmal, (unknown), Pavel G. Komarov, Katerina V. Gurova, Alan C. Sartorelli, Glenn M. Marshall, Murray D. Norris, Andrei V. Gudkov, Michelle Haber	84
20	Reversan, a novel inhibitor of MRP1, increases the therapeutic index of conventional chemotherapeutic agents 2008 ·Cancer Research ·Catherine A. Burkhart, Jayne Murray, (unknown), Marina Pajic, Fujiko Watt, Claudia L. Flemming, Janice Smith, Katerina V. Gurova, Glenn M. Marshall, Murray D. Norris, Andrei V. Gudkov, Michelle Haber	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact